Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3-4-Hypo trial of LT4/LT3 combination versus LT4 monotherapy in autoimmune hypothyroidism with persistent tiredness
NL-OMON59406Phase 3Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levothyroxine sodium and liothyronine in hypothyroidism (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in ThyPRO tiredness subscale score. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
levothyroxine sodiumliothyronine
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NL-OMON59406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59406.